← FDA DRUG APPROVALS

FDA ANDA · ANDA203860

SEVELAMER CARBONATE

Sponsor: INVAGEN PHARMS

APPLICATION
ANDA203860
TYPE
ANDA
ORIGINAL APPROVAL
2017-10-26
LATEST ACTION
2020-12-28
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

SEVELAMER CARBONATEPrescription
SEVELAMER CARBONATE 800MG · TABLET · ORAL

Approval history

2020-12-28Labeling · Supplement 9 · standardAP
2020-04-10Manufacturing (CMC) · Supplement 6 · unknownAP
2017-10-26UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →